Literature DB >> 3220661

Chemical modification of superoxide dismutase. Extension of plasma half life of the enzyme through its reversible binding to the circulating albumin.

T Ogino1, M Inoue, Y Ando, M Awai, H Maeda, Y Morino.   

Abstract

Protection of organisms from oxidative stress is one of the major prerequisites for aerobic life. Since intravenously injected Cu++/Zn++-type superoxide dismutase (SOD) rapidly undergoes renal glomerular filtration and appears in urine in its intact form, its clinical use as a scavenger for superoxide radicals has been highly limited. To test whether reversible interaction of SOD with plasma albumin might decrease the rate of disappearance of the enzyme from the circulation, the lysyl residues of the human erythrocyte-type enzyme were covalently linked with poly-(styrene-co-maleic acid) butyl ester (SMA) via amide linkage. Affinity chromatographic analysis by an albumin-Sepharose column revealed that the enzyme samples labeled with SMA (SMA-SOD) tightly bound to the column, while unmodified SOD was eluted in the unbound fractions. SMA-SOD bound to the column could be eluted by the buffer solution containing 0.1% sodium dodecylsulfate. In vivo analysis revealed that intravenously administered SMA-SOD circulated bound to albumin with an extremely long half-life (6 h), while unmodified SOD rapidly underwent renal glomerular filtration with a plasma half-life of 4 min. Thus, SMA-SOD may effectively dismutase superoxide radicals in the circulation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3220661     DOI: 10.1111/j.1399-3011.1988.tb00675.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  9 in total

1.  Enhanced anti-inflammatory effects of Cu, Zn-superoxide dismutase delivered by genetically modified skin fibroblasts in vitro and in vivo.

Authors:  K Okumura; K Nishiguchi; Y Tanigawara; S Mori; S Iwakawa; F Komada
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

2.  The delivery of superoxide dismutase encapsulated in polyketal microparticles to rat myocardium and protection from myocardial ischemia-reperfusion injury.

Authors:  Gokulakrishnan Seshadri; Jay C Sy; Milton Brown; Sergey Dikalov; Stephen C Yang; Niren Murthy; Michael E Davis
Journal:  Biomaterials       Date:  2009-11-03       Impact factor: 12.479

3.  Recovery of consciousness after an 18-min global cerebral ischemia.

Authors:  Tatsuhiko Kano; Keiji Gotoh; Kohichi Ashimura; Hiraaki Gotoh; Kazufumi Okamoto
Journal:  J Anesth       Date:  1994-12       Impact factor: 2.078

4.  Effects of transfection with the Cu, Zn-superoxide dismutase gene on xanthine/xanthine oxidase-induced cytotoxicity in fibroblasts from rat skin.

Authors:  K Nishiguchi; K Ishida; M Nakajima; T Maeda; F Komada; S Iwakawa; Y Tanigawara; K Okumura
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

5.  Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

Authors:  P Yeh; D Landais; M Lemaître; I Maury; J Y Crenne; J Becquart; A Murry-Brelier; F Boucher; G Montay; R Fleer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

Review 6.  Polymer conjugates. Pharmacokinetic considerations for design and development.

Authors:  R Duncan; F Spreafico
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 7.  Brain delivery of proteins via their fatty acid and block copolymer modifications.

Authors:  Xiang Yi; Alexander V Kabanov
Journal:  J Drug Target       Date:  2013-12       Impact factor: 5.121

Review 8.  Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting.

Authors:  Khaled Greish; Jun Fang; Takao Inutsuka; Akinori Nagamitsu; Hiroshi Maeda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Therapeutic potentials of superoxide dismutase.

Authors:  H Younus
Journal:  Int J Health Sci (Qassim)       Date:  2018 May-Jun
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.